Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Cited by Google
- Similars in SciELO
- Similars in Google
Share
Revista Colombiana de Reumatología
Print version ISSN 0121-8123
Abstract
GOMEZ ESCOBAR, Luis Guillermo and GONZALEZ DEVIA, Deyanira. Possible ocular adverse effects attributable to bisphosphonate therapy: Two case reports ☆. Rev.Colomb.Reumatol. [online]. 2017, vol.24, n.1, pp.54-59. ISSN 0121-8123. https://doi.org/10.1016/j.rcreu.2016.06.002.
Bisphosphonates are used in the management of diseases characterized by an increase in bone resorption such as osteoporosis, metatasic bone disease, malignant hypercalcemia among others. It has been reported that the use of IV bisphosphonates as zoledronate and pamidronate generate ocular adverse effects by an acute phase reaction mediated by an increase of interleukin 6 (IL-6) and tumoral necrosis factor (TNF-a). We present 2 cases, a woman 71 years old and a 67 years old man that received therapy with bisphosphonates and 24 to 72hours later they presented an anterior uveitis.
Keywords : Uveitis; Bisphosphonates; Zoledronic acid; Adverse effect.